BALAXI2023-04-012023-06-30 BALAXI2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member BALAXI2023-06-30 BALAXI2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares BALAXI NOTLISTED BALAXI PHARMACEUTICALS LIMITED Equity 2023-04-01 2024-03-31 2023-08-03 2023-07-27 INR Lakhs First quarter 10:30:00 14:15:00 2023-08-03 2023-08-03 Not applicable Single segment Specialized Wholesale 2023-04-01 2023-06-30 Unaudited Consolidated 659554000.00 -10081000.00 649473000.00 403134000.00 0.00 0.00 68874000.00 2895000.00 2853000.00 99144000.00 576900000.00 72573000.00 -466694000.00 -394121000.00 19340000.00 -31000.00 19309000.00 0.00 -413430000.00 0.00 0.00 0.00 0.00 -413430000.00 51249000.00 -362181000.00 -413430000.00 0.00 -362181000.00 0.00 102302000.00 10 -40.49 -39.93 0.00 0.00 -40.49 -39.93 1. The Unaudited Consolidated Financial Results for the Quarter ended June 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 03, 2023. The Consolidated Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. 2. Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period’s classification.   3. The operating segment of the Group is identified as Specialized Wholesale as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(e ) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company. 4 During the quarter under review, the Angolan currency Kwanza underwent an unprecedented sharp depreciation, falling from 511.50 AOA/USD to 832.5 AOA/USD. Since the creditors in the books of Balaxi Angola are contracted in and due for settlement in USD, this has resulted in a loss on revaluation of 3.65bn AOA( INR 46.66 cr.) including unrealised loss of 3.46bn AOA( INR 44.35 cr.) as of June 30, 2023. The corresponding INR amount has been shown as an exceptional item in the profit and loss statement for the quarter. Balaxi Healthcare Angola has taken several price corrections during the quarter and inventories lying in the books (carried at historical cost as per conservative accounting principles) is now being sold at much higher prices. Administrative Expenses 99144000.00 Exchange differences on translation of foreign operations 51249000.00 51249000.00 0.00 0.00